Emerging targeted therapies for breast cancer Journal Article


Authors: Arnedos, M.; Seidman, A. D.
Article Title: Emerging targeted therapies for breast cancer
Abstract: Breast cancer is the most common neoplasia among women in the world. For the last few years there has been an increasing interest in the development of agents against molecular targets considered to be involved in the process of malignant transformation or tumor progression. Experimental data indicate that various intracellular signaling pathways may be activated or overexpressed in patients who have breast cancer. Targeted therapies against these pathways have recently become one of the most active and promising areas of development in oncology. © 2007 Elsevier Inc. All rights reserved.
Keywords: clinical trial; fatigue; neutropenia; review; doxorubicin; erlotinib; sunitinib; diarrhea; drug efficacy; hypertension; nonhuman; side effect; skin toxicity; antineoplastic agents; paclitaxel; cancer incidence; anorexia; gene targeting; gene overexpression; carboplatin; anemia; mucosa inflammation; nausea; stomatitis; thrombocytopenia; aromatase inhibitor; cyclophosphamide; receptor, epidermal growth factor; breast neoplasms; cancer therapy; cancer mortality; docetaxel; protein tyrosine kinase inhibitor; temsirolimus; asthenia; hyperglycemia; rash; gastrointestinal toxicity; breast carcinoma; gefitinib; tipifarnib; tamoxifen; epirubicin; skin discoloration; protein-tyrosine kinases; headache; letrozole; liver function test; trastuzumab; everolimus; rapamycin; lapatinib; clinical trials; epidermal growth factor receptor kinase inhibitor; mouth pain; geldanamycin; 6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; heat-shock proteins; benzoquinone; lonafarnib
Journal Title: Hematology/Oncology Clinics of North America
Volume: 21
Issue: 2
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2007-04-01
Start Page: 321
End Page: 340
Language: English
DOI: 10.1016/j.hoc.2007.03.005
PUBMED: 17512452
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 3" - "Export Date: 17 November 2011" - "CODEN: HCNAE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Seidman
    318 Seidman